SEARCH

SEARCH BY CITATION

References

  • Escalante AA, Cornejo OE, Freeland DE et al. (2005) A monkey tales: the origin of Plasmodium vivax as a human malaria parasite. Proceedings of National Academy Science of USA 102, 19801985.
  • González-Cerón L, Alvarado-Delgado A, Martínez-Barnetche J et al. (2010) Sequence variation of ookinete surface proteins Pvs25 and Pvs28 of Plasmodium vivax isolates from Southern Mexico and their association to local anophelines infectivity. Infection Genetics and Evolution 10, 645654.
  • Kaslow DC (1992) Transmission-blocking immunity against malaria and other vector-borne diseases. Current Opinion in Immunology 5, 557565.
  • Malkin EM, Durbin AP, Diemert DJ et al. (2005) Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine 23, 31313138.
  • Price RN, Tjitra E, Guerra CA, Yeung S, White NJ & Anstey NM (2007) Vivax malaria: neglected and not benign. American Journal of Tropical Medicine and Hygiene 77, 7987.
  • Sattabongkot J, Tsuboi T, Hisaeda H et al. (2003) Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates. American Journal of Tropical Medicine and Hygiene 69, 536541.
  • Tsuboi T, Kaslow DC, Gozar MM, Tachibana M, Cao YM & Torii M (1998) Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates. Molecular Medicine 4, 772782.
  • Tsuboi T, Kaneko O, Cao YM et al. (2004) A rapid genotyping method for the vivax malaria transmission-blocking vaccine candidates, Pvs25 and Pvs28. Parasitology International 53, 211216.
  • Zakeri S, Razavi S & Djadid ND (2009) Genetic diversity of transmission blocking vaccine candidate (Pvs25 and Pvs28) antigen in Plasmodium vivax clinical isolates from Iran. Acta Tropica 109, 176180.